Schizophrenia review finds drug-specific signals, with limited confirmation
In schizophrenia trials, betahistine improved cognitive scores versus placebo, but that finding came from a single study. Other pooled histamine-targeting drugs showed increased insomnia risk without differences in the other outcomes.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review found a possible cognitive benefit for betahistine in people with schizophrenia, but the supporting result came from a single trial. Separate drugs showed improvements in depressive symptoms, also in individual studies. The other pooled drugs increased insomnia risk. These findings do not demonstrate a consistent benefit across the drug group.
The favorable cognitive and depression findings each relied on an individual study. The abstract does not report treatment durations or translate score changes into everyday functioning.
Why the drugs were separated
The authors analyzed betahistine separately because its actions at histamine receptors differed from those of the other drugs. Its favorable cognitive result therefore should not be treated as evidence that all drugs examined worked similarly.
Different outcomes, different evidence
Betahistine with reboxetine and pitolisant each showed improvements in depressive symptoms in an individual study. Across the remaining outcomes, the review reported no detected differences from placebo; this does not prove equivalent effects.
The original publication
Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis.
Nishii Y, Sakuma K, Hamanaka S et al.
Neuropsychopharmacol Rep · 2025
- PubMed ID
- 40567153
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.